OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
9
Results
Show all
Save search
Copy query
Show results for
Unknown
(9)
Publication Date
Release Date
2022
(2)
2021
(2)
2025
(1)
2019
(1)
2014
(1)
2013
(1)
2011
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Chronic kidney disease after liver transplantation in human immunodeficiency virus/hepatitis C virus-coinfected recipients versus human immunodeficiency virus-infected recipients without hepatitis C virus: results from the National Institutes of Health multi-site study.
Not available
S-EPMC3667971
|
biostudies-literature
Cite
Liver transplantation and cirrhotomimetic hepatocellular carcinoma: classification and outcomes.
Not available
S-EPMC4146426
|
biostudies-literature
Cite
Poor immune response to coronavirus disease vaccines in decompensated cirrhosis patients and liver transplant recipients.
Not available
S-EPMC9595300
|
biostudies-literature
Cite
Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18-49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY).
Not available
S-EPMC8826015
|
biostudies-literature
Cite
Patient-reported outcomes 12 months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP study.
Not available
S-EPMC7969418
|
biostudies-literature
Cite
Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study.
Not available
S-EPMC6959970
|
biostudies-literature
Cite
PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus.
Not available
S-EPMC3736350
|
biostudies-literature
Cite
A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study.
Not available
S-EPMC8639765
|
biostudies-literature
Cite
Acute-on-chronic liver failure (ACLF): the 'Kyoto Consensus'-steps from Asia.
Not available
S-EPMC11846769
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets